The present invention relates to novel radiolabeled compounds for imaging cannabinoid sub-type 1 (CB1) receptors in brains of mammals, particularly humans, using positron emission tomography (PET) or single photon emission computed tomography (SPECT). These radioligands can be used in clinical research, diagnostics, or drug discovery and development, in that, they permit understanding of the role of CB1 receptors in neuropsychiatric disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, multiple sclerosis, depression, mood disorder, anxiety, schizophrenia, drug addiction, alcohol disorder, obesity and anorexia.
The principal radioligand under the claim is effective for imaging CB1 receptors in vivo with PET.
Primary radioligand has been evaluated in non-human primates with PET.
Radioligands may be useful for performing drug occupancy studies of CB1 receptors, and for neuropsychiatric studies and investigations with imaging techniques (e.g., PET or SPECT).
U.S. Provisional Application No. 61/052,581 filed 12 May 2008 (HHS Reference No. E-155-2008/0-US-01)
Victor W. Pike (NIMH), Sean R. Donohue (NIMH), et al.
Available for exclusive or non-exclusive licensing.
Rung C Tang
Licensing and Patenting Manager
Office of Technology Transfer
The NIH supports and conducts basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases.View profile
Clients in focus...